Pelareorep — Investigational Agent
Other · Phase 2 · Oncolytics Biotech
Mechanism of Action
Pelareorep is an intravenously administered, non-genetically-modified oncolytic reovirus (Reovirus Type 3 Dearing). It preferentially infects and replicates within tumor cells that have activated RAS signaling, which impairs the antiviral interferon response that normally protects healthy cells — giving the virus selective tropism for transformed cells. Viral replication triggers direct oncolysis and immunogenic cell death, releasing tumor antigens and danger signals that recruit and activate cytotoxic T cells and increase tumor-infiltrating lymphocytes. By converting immunologically 'cold'…
Investigational Indications
- Second-line or later squamous cell carcinoma of the anal canal (SCAC), in combination with a checkpoint inhibitor
- KRAS-mutated, microsatellite-stable (MSS) metastatic colorectal cancer
- Metastatic pancreatic ductal adenocarcinoma
- Metastatic breast cancer (earlier-phase evaluation)
- Multiple myeloma and other hematologic malignancies (earlier-phase evaluation)